MX2009001770A - Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida. - Google Patents

Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida.

Info

Publication number
MX2009001770A
MX2009001770A MX2009001770A MX2009001770A MX2009001770A MX 2009001770 A MX2009001770 A MX 2009001770A MX 2009001770 A MX2009001770 A MX 2009001770A MX 2009001770 A MX2009001770 A MX 2009001770A MX 2009001770 A MX2009001770 A MX 2009001770A
Authority
MX
Mexico
Prior art keywords
formula
compound
salt
temperature
salt form
Prior art date
Application number
MX2009001770A
Other languages
English (en)
Spanish (es)
Inventor
Jianguo Yin
Ho-Jane Shue
David J Blythin
Xiao Chen
Xiaoyong Fu
Rongze Kuang
Vincenzo Liotta
Xiaoming Chen
Scott Trzaska
Chee-Wah Tang
Zaher Shabani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009001770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009001770A publication Critical patent/MX2009001770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2009001770A 2006-08-14 2007-08-10 Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida. MX2009001770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14
PCT/US2007/017848 WO2008021271A1 (en) 2006-08-14 2007-08-10 Salts of 5 - ( l ( s ) -amino - 2 - hydroxyethyl ) -n- [ ( 2, 4 -difluorophenyl) -methyl] - 2 - [ 8 -methoxy - 2 - (trifluoromethyl) - 5 - quinoline] - 4 - oxazolecarboxamide

Publications (1)

Publication Number Publication Date
MX2009001770A true MX2009001770A (es) 2009-02-25

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001770A MX2009001770A (es) 2006-08-14 2007-08-10 Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida.

Country Status (11)

Country Link
US (1) US7956189B2 (https=)
EP (1) EP2069337A1 (https=)
JP (3) JP2010500406A (https=)
CN (1) CN101522671A (https=)
AR (1) AR062373A1 (https=)
CA (1) CA2660703A1 (https=)
CL (1) CL2007002366A1 (https=)
MX (1) MX2009001770A (https=)
PE (1) PE20080424A1 (https=)
TW (1) TW200819446A (https=)
WO (1) WO2008021271A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) * 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren

Also Published As

Publication number Publication date
CL2007002366A1 (es) 2008-03-14
JP2013032394A (ja) 2013-02-14
JP2010500406A (ja) 2010-01-07
CN101522671A (zh) 2009-09-02
US20080108818A1 (en) 2008-05-08
TW200819446A (en) 2008-05-01
EP2069337A1 (en) 2009-06-17
US7956189B2 (en) 2011-06-07
JP2012176989A (ja) 2012-09-13
AR062373A1 (es) 2008-11-05
WO2008021271A1 (en) 2008-02-21
CA2660703A1 (en) 2008-02-21
PE20080424A1 (es) 2008-04-28

Similar Documents

Publication Publication Date Title
MX2009001770A (es) Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida.
CN103804356A (zh) 4-甲基-n-[3-（4-甲基-咪唑-1-基）-5-三氟甲基-苯基]-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯甲酰胺的晶形
US20240279265A1 (en) Crystal forms of glucosamine derivative, and preparation method therefor and use thereof
TWI727517B (zh) 貝前列素-314d晶體及其製備方法
KR20250003750A (ko) [2-(1h-인돌-3-일)-1h-이미다졸-4-일](3,4,5-트리메톡시페닐)메타논 및 이의 염의 다형체
TWI724651B (zh) 貝前列素-314d單水合物晶體及其製備方法
TWI801759B (zh) 十六烷基曲前列環素晶體及其製備方法
RU2335502C2 (ru) Полиморфы пирролзамещенных 2-индолиноновых ингибиторов протеинкиназы
Feth et al. From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor
WO2007114922A2 (en) Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
US20240158378A1 (en) Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor
US20070225507A1 (en) Process for preparing a crystalline form of Tegaserod maleate
TW202334098A (zh) 吡嗪類衍生物的鹽的晶型及其製備方法
JP2025525196A (ja) （Ｓ）－７－オキサ－２－アザ－スピロ［４．５］デカン－２－カルボン酸［７－（３，６－ジヒドロ－２Ｈ－ピラン－４－イル）－４－メトキシ－チアゾロ［４，５－ｃ］ピリジン－２－イル］－アミドの新規結晶形態およびその共結晶形態
TW202527943A (zh) 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式
WO2025180349A9 (zh) 化合物的固体及其制备方法和用途
CN116120380A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
CN121471170A (zh) 化合物盐酸盐的晶型及其制备方法和用途
CN115246830A (zh) 一种酸的固体形式及其制备方法
EP3510019A1 (en) Crystalline salts of betrixaban
US20090062546A1 (en) Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof
WO2019133462A1 (en) Solid state forms of pemafibrate
TW201636346A (zh) 二－匹多莫德苄乙二胺及其固體型

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status